Recent researchers found the knockdown of ENO3 exhibits anticancer effect in STK11 mutant cells and suggest that ENO3-based targeted therapy might be promising for lung cancer patients harboring STK11 mutations (30). This evidence concerns the gene ENO3 and lung cancer.